Zurcher Kantonalbank Zurich Cantonalbank Has $401,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 32.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 40,658 shares of the company’s stock after acquiring an additional 10,033 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Recursion Pharmaceuticals were worth $401,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in RXRX. ARK Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after acquiring an additional 13,777,689 shares during the last quarter. Vanguard Group Inc. raised its position in Recursion Pharmaceuticals by 37.7% in the third quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock valued at $118,627,000 after purchasing an additional 4,247,002 shares during the last quarter. FMR LLC boosted its stake in shares of Recursion Pharmaceuticals by 134.4% during the third quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after purchasing an additional 6,129,935 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Recursion Pharmaceuticals by 161.2% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock worth $90,749,000 after purchasing an additional 5,680,656 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Recursion Pharmaceuticals by 15.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock valued at $8,858,000 after buying an additional 157,189 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $9.30, for a total value of $106,457.10. Following the transaction, the director now directly owns 7,312,917 shares of the company’s stock, valued at $68,010,128.10. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $9.30, for a total value of $106,457.10. Following the completion of the sale, the director now owns 7,312,917 shares in the company, valued at approximately $68,010,128.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Gibson sold 48,272 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $9.22, for a total transaction of $445,067.84. Following the transaction, the chief executive officer now directly owns 774,703 shares in the company, valued at $7,142,761.66. The disclosure for this sale can be found here. Insiders have sold a total of 412,665 shares of company stock worth $4,036,978 in the last 90 days. Corporate insiders own 19.96% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $8.84 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.80 and a 52 week high of $16.75. The firm’s fifty day moving average is $9.97 and its 200-day moving average is $9.16. The firm has a market cap of $2.07 billion, a P/E ratio of -5.83 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The business had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $12.37 million. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on RXRX shares. KeyCorp lifted their target price on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC reissued a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Finally, TD Cowen initiated coverage on Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating for the company. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.